MaxCyte (MXCT) vs NRC Health (NRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NRC Health (NRC) has outperformed MaxCyte (MXCT) over the past year, gaining 42.5% versus a loss of 18.0%. Over five years, NRC leads with a -39.0% price change compared with -85.9% for MXCT. NRC Health is the larger company by market cap ($533.9 million vs $141.5 million), about 3.8 times the size.
NRC Health pays a dividend yielding 2.54%, while MaxCyte does not currently pay one. NRC Health converts more of its revenue into profit, with a net margin of 8.4% versus -135.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MXCT | NRC |
|---|---|---|
| Share price | $1.37 | $25.16 |
| Market cap | $141.45M | $533.93M |
| 1-day change | +7.03% | +0.68% |
| YTD return | -11.61% | +34.04% |
| 1-year return | -17.96% | +42.47% |
| 5-year return | -85.92% | -38.98% |
| P/E ratio (TTM) | — | 93.19 |
| Forward P/E | — | 23.74 |
| EPS (TTM) | $-0.26 | $0.27 |
| Dividend yield | 0.00% | 2.54% |
| Annual dividend | $0.00 | $0.64 |
| Revenue (latest FY) | $33.03M | $137.39M |
| Revenue growth (YoY) | -14.50% | -3.96% |
| Net income (latest FY) | $-44.63M | $11.60M |
| Gross margin | 81.16% | — |
| Operating margin | -157.14% | 16.44% |
| Net margin | -135.14% | 8.44% |
| 52-week high | $1.80 | $27.60 |
| 52-week low | $0.643 | $11.74 |
| Distance from 52-week high | -23.89% | -8.84% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +200.00% | +7.31% |
| Average volume | 1.04M | 110.81K |
| Shares outstanding | 103.25M | 21.22M |
| Employees | 91 | 357 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRC Health is about 3.8 times larger than MaxCyte by market value ($533.93M vs $141.45M).
- NRC has outperformed MXCT by 60.4 percentage points over the past year.
- NRC Health offers a meaningfully higher dividend yield (2.54% vs 0.00%).
- NRC Health is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -135.1 cents for MaxCyte.
- NRC Health grew revenue faster in its latest fiscal year (-3.96% vs -14.50%).
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees
About NRC Health
NRC stock →NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and consistency of healthcare brands; assessment of differentiators; and segmentation tools to evaluate the needs, wants, and behaviors of communities through assessments.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 357 employees
MXCT vs NRC FAQ
Which is bigger, MaxCyte or NRC Health?
NRC Health (NRC) is larger, with a market capitalization of $533.93M compared with $141.45M for MaxCyte (MXCT).
Which stock has performed better over the past year, MXCT or NRC?
NRC returned +42.47% over the past 12 months, compared with -17.96% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, MaxCyte or NRC Health?
NRC Health pays a dividend yielding 2.54%, while MaxCyte does not currently pay a regular dividend.
Are MaxCyte and NRC Health in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.